Traditional mass spectrometry-based proteomics demands substantial sample quantities—typically 5×10⁷ cells or tissues weighing at least 30mg. Yet in real research scenarios, many precious biological samples simply cannot meet these requirements. Think of flow-sorted cell populations, primary cultured cells, clinical biopsy tissues, or specialty samples like ocular fluids and vitreous humor.
Figure 1. Data-independent acquisition (DIA)has revolutionized mass spectrometry–based proteomics by yielding unbiased, high-accuracy, and reproducible data. (Source: Fröhlich K, et al. 2024)
Micro-proteomics (Low-Input Proteomics) emerged precisely to address this technical barrier. Through innovative sample preparation techniques and advanced mass spectrometry strategies, we can now extract precise protein identification and quantification from trace-amount samples at the microgram level. This approach excels at capturing low-abundance peptides while dramatically improving detection sensitivity, reproducibility, and analytical depth—opening doors that were previously closed to researchers working with limited, irreplaceable biological material.
Our micro-proteomics service combines two transformative technologies:
Analyzable Sample Types
| Sample Category | Specific Sample Type | Application Value |
| Cell Samples | Flow-sorted cell populations | High-throughput protein quantification of specific cell subsets; investigation of cellular heterogeneity |
| Primary cultured cells | Cells derived from clinical or experimental tissues; preservation of native cell properties | |
| Rare cell sources | Stem cells, tumor cells, immune cells and other scarce cell types—comprehensive protein profiling | |
| Tissue and Biopsy Samples | Clinical needle biopsies | Minute tissue samples from tumors, liver—identification of diagnostic protein biomarkers |
| Micro-tissue specimens | Precious tissue fragments from surgery; fresh-frozen or long-term stored tissue | |
| Body Fluids and Special Samples | Ocular fluids | Vitreous humor, aqueous humor—ophthalmic diagnostic samples and disease mechanism research |
| Cerebrospinal fluid (CSF) | Biomarker studies for neurological diseases; early detection of Alzheimer's, Parkinson's, and related disorders | |
| Blood-derived materials | Plasma exosomes, circulating tumor cells, peripheral blood mononuclear cells |
Compared to conventional proteomics approaches, our service delivers remarkable breakthroughs across multiple dimensions. We've drastically reduced sample requirements to just a fraction of traditional demands, enabling analysis of precious clinical samples that were previously off-limits. Our DIA-based strategy dramatically enhances capture efficiency for low-abundance peptides, maintaining exceptional reproducibility while detecting thousands of proteins per analysis—substantially expanding your research capabilities. We support both absolute and relative quantification, post-translational modification analysis, and comprehensive bioinformatics interpretation, with rapid turnaround times and standardized workflows ensuring result consistency and comparability across analyses.
Micro-proteomics represents a critical breakthrough in modern bioanalytical technology. By reducing sample requirements to the microgram scale, we've unlocked the door to deep analysis of irreplaceable biological specimens. Whether your research focuses on basic discovery, clinical diagnostics, or drug development target identification, Creative Diagnostics delivers accurate, dependable, and efficient proteomics data support. Leveraging cutting-edge DIA mass spectrometry and standardized analytical workflows, we're committed to helping researchers extract valuable biological insights from trace samples—advancing precision medicine and accelerating the pace of life sciences discovery.
Reference